Home > Quotes > NBS

Neostem, Inc. Stock Quote & Summary Data

NBS 
$0.5775
*  
unch
  negative  
unch
Get NBS Alerts
*Delayed - data as of May 22, 2013 15:43 ET 
Exchange: AMEX
Industry: Health Care
Community Rating:
View:    NBS After Hours
 
 

Symbol List Views

Stock Details

CHARTS

COMPANY NEWS

STOCK ANALYSIS

FUNDAMENTALS

HOLDINGS

 Save stocks for next time
 | Sponsored

 Intraday Chart

5d | 1m | 6m | 12m | More Charting


 Company Description (as filed with the SEC)

NeoStem, Inc. (“we,” “NeoStem” or the “Company”) is a leader in the emerging cellular therapy industry. Cellular therapy addresses the process by which new cells are introduced into a tissue to prevent or treat disease, or regenerate damaged or aged tissue, and comprises a separate therapeutic technology platform in addition to the current three pillars of healthcare: pharmaceuticals, biologics and medical devices. Modern cell-based therapies have progressed from the first recorded human to human blood transfusion 200 years ago through to the advanced cellular therapies of today including bone marrow and organ transplantation, tissue banking and reproductive in vitro fertilization and future therapies being investigated to treat cancer, cardiologic, neurologic, ophthalmic and orthopedic diseases among others.  ... More ...  



News Headlines for NBS

 

Consensus Recommendation